Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 7/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.37 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.34 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1483172 | 0.89 | HIF1A (0.42) | HIF1AHDAC1HDAC2HDAC3PDCD1 | |
| SCHEMBL8004129 | 0.89 | ROCK2 (0.40) | HIF1AHDAC1HDAC2HDAC3NCOR2 | |
| SCHEMBL1497014 | 0.87 | HIF1A (0.48) | HIF1AHDAC1HDAC2HDAC3ROCK1 | |
| SCHEMBL1496916 | 0.87 | HIF1A (0.42) | HIF1AHDAC1ALDH1A1KDM4ENPC1 | |
| SCHEMBL1496888 | 0.87 | ROCK1 (0.40) | HIF1AHDAC1HDAC2HDAC3PDCD1 | |
| SCHEMBL8004725 | 0.86 | PDCD1 (0.37) | HDAC1HDAC2HDAC3NCOR2HDAC10 | |
| SCHEMBL8001278 | 0.85 | HDAC2 (0.39) | HDAC1HDAC2HDAC3NPC1RAB9A | |
| SCHEMBL8001655 | 0.85 | HDAC1 (0.43) | HDAC1HDAC2HDAC3NCOR2HDAC10 | |
| SCHEMBL8001271 | 0.85 | HIF1A (0.41) | HIF1AHDAC1HDAC2HDAC3ALDH1A1 | |
| SCHEMBL7988715 | 0.84 | ROCK1 (0.41) | HDAC1HDAC2HDAC3NCOR2HDAC10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288380-B2 | Thiophenediamine derivative having urea structure | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120202808-A1 | NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| US-8198271-B2 | Thiophenediamine derivative having urea structure | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-06-12 | — | — | US | disclosed |
| US-20110077244-A1 | NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-03-31 | — | — | US | disclosed |
| EP-2292611-A1 | NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE | Santen Pharmaceutical Co., Ltd (JP) | 2011-03-09 | — | — | EP | disclosed |
| WO-2009142321-A1 | NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE | 参天製薬株式会社 (JP) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202808-A1 | NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE | CBR1, NAT1, PRMT1 | HIF1A 1202/4885HDAC1 893/4885HDAC2 2017/4885 |
| US-20110077244-A1 | NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE | HNMT, HRH4, CHRM1 | HIF1A 2109/4885HDAC1 986/4885HDAC2 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.